IAP antagonization promotes inflammatory destruction of vascular endothelium

In this study, we show for the first time that the therapeutic antagonization of inhibitor of apoptosis proteins (IAPs) inhibits B16 melanoma growth by disrupting tumor vasculature. Specifically, the treatment of mice bearing B16 melanoma with an IAP antagonist compound A (Comp A) inhibits tumor growth not by inducing direct cytotoxicity against B16 cells but rather by a hitherto unrecognized antiangiogenic activity against tumor vessels. Our detailed analysis showed that Comp A treatment induces NF‐κB activity in B16 tumor cells and facilitates the production of TNF. In the presence of Comp A, endothelial cells (ECs) become highly susceptible to TNF and undergo apoptotic cell death. Accordingly, the antiangiogenic and growth‐attenuating effects of Comp A treatment were completely abolished in TNF‐R knockout mice. This novel targeting approach could be of clinical value in controlling pathological neoangiogenesis under inflammatory condition while sparing blood vessels under normal condition.

[1]  E. Rugarli,et al.  BID‐dependent release of mitochondrial SMAC dampens XIAP‐mediated immunity against Shigella , 2014, The EMBO journal.

[2]  Yigong Shi,et al.  Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. , 2014, Journal of medicinal chemistry.

[3]  M. Hallek,et al.  Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing , 2014, EMBO molecular medicine.

[4]  Yigong Shi,et al.  Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models , 2014, Molecular Cancer Therapeutics.

[5]  R. Korneluk,et al.  Smac mimetics and innate immune stimuli synergize to promote tumor death , 2014, Nature Biotechnology.

[6]  M. Colombo,et al.  Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity , 2013, Cell Death and Disease.

[7]  Michael J. Schell,et al.  Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. , 2013, Cell reports.

[8]  H. Pehamberger,et al.  The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells , 2013, Clinical Cancer Research.

[9]  M. Odenthal,et al.  TNF-induced target cell killing by CTL activated through cross-presentation. , 2012, Cell reports.

[10]  R. Korneluk,et al.  cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation , 2012, Cell Death and Differentiation.

[11]  D. Vaux,et al.  IAPs limit activation of RIP kinases by TNF receptor 1 during development , 2012, The EMBO journal.

[12]  Simone Fulda,et al.  Targeting IAP proteins for therapeutic intervention in cancer , 2012, Nature Reviews Drug Discovery.

[13]  H. Wajant,et al.  SMAC Mimetic BV6 Induces Cell Death in Monocytes and Maturation of Monocyte-Derived Dendritic Cells , 2011, PloS one.

[14]  P. Vandenabeele,et al.  Molecular mechanisms of necroptosis: an ordered cellular explosion , 2010, Nature Reviews Molecular Cell Biology.

[15]  N. Hacohen,et al.  IAP inhibitors enhance co-stimulation to promote tumor immunity , 2010, The Journal of experimental medicine.

[16]  H. Kashkar.  X-linked Inhibitor of Apoptosis: A Chemoresistance Factor or a Hollow Promise , 2010, Clinical Cancer Research.

[17]  J. Minna,et al.  Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner , 2010, Cell Death and Differentiation.

[18]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[19]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[20]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[21]  Hao Wu,et al.  Smac Mimetics and TNFα: A Dangerous Liaison? , 2007, Cell.

[22]  J. Reed,et al.  Birc2 (cIap1) regulates endothelial cell integrity and blood vessel homeostasis , 2007, Nature Genetics.

[23]  A. Eggermont,et al.  TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.

[24]  Bart Landuyt,et al.  Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.

[25]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[26]  D. Vaux,et al.  PHAGOCYTES , GRANULOCYTES , AND MYELOPOIESIS cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK 1-and RIPK 3-dependent manner , 2014 .

[27]  Y. Sekido,et al.  Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .

[28]  Vishva M Dixit,et al.  IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. , 2007, Cell.

[29]  Vinay Tergaonkar,et al.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. , 2007, Cell.

[30]  Hao Wu,et al.  Smac mimetics and TNFalpha: a dangerous liaison? , 2007, Cell.